X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BP-C2
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: BP-C2
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
BP-C2 reduces mortality when administered 24 hours post-exposure in a murine model of severe, radiation-induced gastrointestinal acute radiation syndrome (GI-ARS).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BP-C2
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: BP-C2
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: $5.9 million Upfront Cash: Undisclosed
Deal Type: Funding May 25, 2020
Details:
This three-year contract consists of a one-year base period with two one-year optional periods that will allow Meabco to complete IND-enabling studies and advance BP-C2 as a therapy for treating the effects of unintentional radiation exposure.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
